FOLH1 and neoplasm: Consistent with this, our data also showed 177Lu-rhPSMA-10.1 to have a favorable biodistribution profile compared with 177Lu-PSMA-I&T, with a 6.5-fold lower kidney uptake at 12 h and a more favorable tumor-to-kidney ratio than 177Lu-PSMA-I&T.